CryLife inks deal to buy Cardiogenesis
Atlanta, Ga.-based CryoLife, a biological medical device company, has signed a deal to buy Cardiogenesis for $22 million, according to FierceMedicalDevices. The Irvine, Calif.-based developer develops surgical products for patients with refractory angina as a result of diffuse coronary artery disease. Cardiogenesis' technology is used for Transmyocardial Revascularization (TMR), which treats patients with angina that is not responsive to medications.
"Cardiogenesis brings developed technologies with proven clinical outcomes in the treatment of cardiovascular disease and a pipeline of potential new products that build on the TMR platform," said CryoLife CEO Steven Anderson. "Cardiogenesis' products greatly expand our customer offerings and we believe they will create opportunities for us to cross sell and rollout Cardiogenesis' products on a global platform."